Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LQWD Technologies Lightning Network Infrastructure Surpasses 1 Million Global Transactions (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Revive Therapeutics Ltd C.RVV

Alternate Symbol(s):  RVVTF

Healthcare
Revive Therapeutics Ltd. is a Canada-based life sciences company. The Company is focused on the research and development of therapeutics and diagnostics for infectious diseases, medical countermeasures, and rare disorders. It is engaged in exploring the use of Bucillamine for the potential treatment of nerve agent exposure and long COVID. The Company, through its diagnostics division, is... see more

Recent & Breaking News (CSE:RVV)

Revive Therapeutics Provides Update on the Psilocybin Clinical Study for Methamphetamine Use Disorder and Oral Psilocybin Thin Film Strip Program

GlobeNewswire September 16, 2022

CSE Bulletin: INDEX - CSE 25 INDEX QUARTERLY REBALANCING

Newsfile September 15, 2022

Revive Therapeutics (CSE:RVV) submits amended Phase 3 COVID-19 study protocol to FDA

John Ballem  September 14, 2022

Revive Therapeutics Announces Submission of Amended Phase 3 COVID-19 Study Protocol to FDA

GlobeNewswire September 14, 2022

Update from Revive Therapeutics (CSE:RVV) on Phase 3 clinical trial for Bucillamine in COVID-19

John Ballem  August 16, 2022

Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19

GlobeNewswire August 16, 2022

Update from Revive Therapeutics (CSE:RVV) on Phase 3 clinical trial for Bucillamine in COVID-19

Dave Jackson July 25, 2022

Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19

GlobeNewswire July 25, 2022

Revive (CSE:RVV) advancing COVID-19 drug

Caroline Egan  June 24, 2022

Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19

GlobeNewswire June 24, 2022

Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19

GlobeNewswire June 6, 2022

Revive Therapeutics Advances Inflammatory Liver Disorders Programs for Autoimmune Hepatitis and Liver Transplantation

GlobeNewswire May 31, 2022

Revive (CSE:RVV) gets FDA OK for Bucillamine trials to treat COVID-19

Caroline Egan  May 26, 2022

Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19

GlobeNewswire May 26, 2022

Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19

GlobeNewswire May 16, 2022

PharmaTher Reports Financial Results for the Third Quarter of Fiscal 2022 and Provides Recent Business Highlights and Update

GlobeNewswire April 25, 2022

Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19

GlobeNewswire April 25, 2022

Revive Therapeutics (CSE:RVV) confirms effectiveness of Bucillamine

Caroline Egan  April 18, 2022

Revive Therapeutics Announces Publication of Research Data with Bucillamine in COVID-19

GlobeNewswire April 18, 2022

Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19

GlobeNewswire April 11, 2022